RxDoctor Payments Data

Jay Jordan, MD

Cardiovascular Disease · Los Angeles, CANPI 1265446371

Payments from drug & device makers

$5,297in general payments, 2019–2025

Across 271 payments — averaging $19.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Novartis$482
  • Amgen$376
  • AbbVie$374
  • QOL Medical, LLC$238
  • Amarin Pharma, Inc.$232
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$5,297100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,297 in reported general payments places this provider in the 60th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$125,065
Medicare patients
172
Services billed
1,776

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Zileuton ErZileuton38$108,946
Clemastine Fumarate13$104,494
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate62$86,727
Metformin Er GastricMetformin Hcl42$83,768
EliquisApixaban77$77,624
XareltoRivaroxaban52$41,200
Dihydroergotamine Mesylate25$38,304
JardianceEmpagliflozin30$20,378
OzempicSemaglutide22$20,219
Repatha SureclickEvolocumab30$18,293
MounjaroTirzepatide18$18,157
LinzessLinaclotide22$14,409
VascepaIcosapent Ethyl22$7,623
JanuviaSitagliptin Phosphate11$6,331
Diclofenac Sodium24$5,739

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$70$77,62477 claims
Johnson & JohnsonXarelto$147$41,20052 claims
Boehringer IngelheimJardiance$20$20,37830 claims
AbbVieLinzess, Synthroid$374$18,45458 claims
Lilly USA, LLCMounjaro$80$18,15718 claims
MerckJanuvia$142$6,33111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →